CVRx Revenue Rises 16% but Cuts Full-Year Outlook on Sales Force Challenges
Event summary
- CVRx reported $15.7M in Q2 2026 revenue, up 16% YoY, with U.S. revenue growing 21%.
- Active implanting centers in the U.S. increased to 258 from 240 year-over-year.
- Humana issued a Medicare Advantage coverage policy for Barostim therapy effective May 2026.
- CVRx cut its full-year revenue outlook to $58M–$60M, citing fewer sales territories and lower sales force productivity.
The big picture
CVRx’s revenue growth reflects expanding U.S. adoption of Barostim therapy, but operational challenges in sales force execution have led to a revised outlook. The Humana coverage policy marks a strategic win for reimbursement, yet the company must navigate payer negotiations and clinical trial outcomes to sustain long-term growth.
What we're watching
- Sales Force Dynamics
- How CVRx’s actions to address sales force productivity will impact Q3 revenue.
- Reimbursement Progress
- Whether Humana’s Medicare Advantage coverage policy will drive further adoption of Barostim therapy.
- Clinical Trial Momentum
- The pace at which the BENEFIT-HF trial advances and its potential to expand the addressable market.
Related topics